BUSINESS

Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan

April 1, 2020
Fujifilm Toyama Chemical officially announced the launch of a Japanese PIII clinical trial for its anti-flu drug Avigan (favipiravir) on March 31 for the treatment of the novel coronavirus disease COVID-19, aiming to enroll some 100 patients and complete the…

To read the full story

Related Article

BUSINESS

By Eric Persoff

The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…

By Yoshinori Sagehashi

The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…

By Yoshinori Sagehashi

“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…